SHARP

NCT00105443 📎

Regimen

Experimental
sorafenib 400 mg BID
Control
placebo

Population

Advanced hepatocellular carcinoma, no prior systemic therapy

Key finding

mOS 10.7 vs 7.9 mo (HR 0.69, 95% CI 0.55-0.87, p<0.001); mTTP radiologic 5.5 vs 2.8 mo; no difference in time to symptomatic progression; **~3-month OS improvement was first ever positive systemic Rx in HCC**; predominantly European/Western cohort (HCV ~28%, alcohol ~26%, HBV ~19%)

Source: PMID 18650514

Timeline

    Guideline citations

    • NCCN HCC (p.67)